Greg Bosch brings over 35 years in healthcare to Panavance with global leadership of commercial, operations, and R&D teams. His general management experience in the life science industry spans the pharmaceutical, biologics, biosurgery and medical device segments including acquisitions of public and private companies, private financings as well as taking a company public.  Prior to joining Panavance Greg was Chief Executive Officer of Geistlich Pharma North America where he led a cross functional team to achieve the market leadership position in regenerative medicine in the US dental field. While at Geistlich, he also led the company’s oncology program and was responsible for the team developing Panavance’s proprietary small molecule drug compound GP-2250 from early R&D through to the clinical studies. Earlier in his career he was the President and Chief Executive Officer of PuriCore PLC where he led a successful IPO on the London Stock Exchange. Prior to his experience with PuriCore he held roles of increasing responsibility at Baxter International with international assignments in Switzerland and Austria including General Manager of the BioSurgery Business, Vice President of Strategic Planning and Assistant to the President. Greg currently serves on the Boards of Kibow Biotech and Panavance Therapeutics Inc. Greg earned his B.A. in Public Policy from Duke University and MBA from DePaul University.